Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Lung Cancer

  Free Subscription


1 AJR Am J Roentgenol
1 Arch Pathol Lab Med
3 BMC Cancer
1 Cancer Res
3 Clin Cancer Res
3 Clin Nucl Med
4 Eur J Cardiothorac Surg
2 Eur Respir J
3 Int J Cancer
1 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
8 J Clin Oncol
3 J Surg Oncol
1 J Thorac Oncol
3 JAMA Oncol
1 Lancet Oncol
1 Mol Cancer Ther
1 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. HOCHHEGGER B, Braithwaite D
    Beyond the AJR: Should Imaging-Based Risk Assessment Tools Be Used in Lung Cancer Screening?
    AJR Am J Roentgenol. 2023 Feb 1. doi: 10.2214/AJR.23.29060.

    Arch Pathol Lab Med

  2. NOVA-CAMACHO LM, Gomez-Dorronsoro M, Guarch R, Cordoba A, et al
    Cardiac Metastasis From Solid Cancers: A 35-Year Single-Center Autopsy Study.
    Arch Pathol Lab Med. 2023;147:177-184.
    PubMed         Abstract available

    BMC Cancer

  3. XU H, Zhu N, Yue Y, Guo Y, et al
    Spectral CT-based radiomics signature for distinguishing malignant pulmonary nodules from benign.
    BMC Cancer. 2023;23:91.
    PubMed         Abstract available

  4. ZHANG L, Zhao K, Kuang T, Wang K, et al
    The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy.
    BMC Cancer. 2023;23:101.
    PubMed         Abstract available

  5. LI J, Li J, Hao H, Lu F, et al
    Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma.
    BMC Cancer. 2023;23:110.
    PubMed         Abstract available

    Cancer Res

  6. KIM N, Hwang CY, Kim T, Kim H, et al
    A cell fate reprogramming strategy reverses epithelial-to-mesenchymal transition of lung cancer cells while avoiding hybrid states.
    Cancer Res. 2023 Sep 13:CAN-22-1559. doi: 10.1158/0008-5472.CAN-22-1559.
    PubMed         Abstract available

    Clin Cancer Res

  7. WANG J, Guo W, Wang X, Tang X, et al
    Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
    Clin Cancer Res. 2023;29:659-666.
    PubMed         Abstract available

  8. AUGUSTIN RC, Bao R, Luke JJ
    Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones.
    Clin Cancer Res. 2023;29:505-507.
    PubMed         Abstract available

  9. LEE HS, Jang HJ, Ramineni M, Wang DY, et al
    A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2023;29:548-559.
    PubMed         Abstract available

    Clin Nucl Med

  10. OUVRARD E, Voulleminot P, Mennecier B, Bund C, et al
    18FDG PET/CT Tumoral and Neurologic Therapeutic Response in a Case of Anti-GABABR Paraneoplastic Limbic Encephalitis.
    Clin Nucl Med. 2023;48:237-239.
    PubMed         Abstract available

  11. HOU G, Peng P, Zhao Y, Zheng R, et al
    The Humeral Metastasis as the Initial Presentation of Lung Adenocarcinoma Revealed by 18F-FDG PET/CT.
    Clin Nucl Med. 2023;48:280-281.
    PubMed         Abstract available

  12. CHENG Y, Li WM, Wang SX, Shao D, et al
    PET/CT Manifestations of a Case of Penicilliosis Marneffei Misdiagnosed as Lung Cancer.
    Clin Nucl Med. 2023 Jan 12. doi: 10.1097/RLU.0000000000004531.
    PubMed         Abstract available

    Eur J Cardiothorac Surg

  13. HAGEN JA
    Tumor location predicts occult N1 nodal metastases in clinical stage I non-small cell lung cancer: is location alone sufficient to justify limiting the extent of resection.
    Eur J Cardiothorac Surg. 2023 Feb 1:ezad033. doi: 10.1093.

  14. KAMIGAICHI A, Aokage K, Ikeno T, Wakabayashi M, et al
    Long-term Survival Outcomes after Lobe-specific Nodal Dissection in Patients with Early Non-Small Cell Lung Cancer.
    Eur J Cardiothorac Surg. 2023 Jan 30:ezad016. doi: 10.1093.
    PubMed         Abstract available

  15. AKAMINE T, Yotsukura M, Yoshida Y, Nakagawa K, et al
    Feasibility and effectiveness of segmentectomy versus wedge resection for clinical stage I non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2023 Jan 27:ezad018. doi: 10.1093.
    PubMed         Abstract available

  16. BAKHUIS W, Kersten CM, Sadeghi AH, Mank QJ, et al
    Preoperative visualization of congenital lung abnormalities: hybridizing artificial intelligence and virtual reality.
    Eur J Cardiothorac Surg. 2022;63:ezad014.
    PubMed         Abstract available

    Eur Respir J

  17. RAMI-PORTA R, Fong KM
    Stage IV lung cancer: the relevance of tumour profile for the construction of prognostic groups.
    Eur Respir J. 2023;61:2202094.

  18. WANG XF, Li QY
    Optimised surveillance of minor to moderate bronchial dysplasia in a risky population: more precision strategies needed.
    Eur Respir J. 2023;61:2202264.

    Int J Cancer

  19. VAN GULIJK M, Belderbos B, Dumoulin D, Cornelissen R, et al
    Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.
    Int J Cancer. 2023;152:1438-1443.
    PubMed         Abstract available

  20. SUN C, Nagaoka K, Kobayashi Y, Maejima K, et al
    Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.
    Int J Cancer. 2023;152:1463-1475.
    PubMed         Abstract available

  21. ZHANG Y, Liu W, Zhang H, Sun B, et al
    Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma.
    Int J Cancer. 2023;152:1490-1500.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  22. SAVLA B, Hamza MA, Yacubovich D, Cobbs S, et al
    The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 28:S0360-3016(23)00080.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  23. WANG M, Liu L, Dai Q, Jin M, et al
    Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC.
    J Cancer Res Clin Oncol. 2023;149:247-261.
    PubMed         Abstract available

  24. LI Q, Tang Y, Wang T, Zhu J, et al
    Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:307-323.
    PubMed         Abstract available

  25. ZHANG X, Gao H, Dang S, Dai L, et al
    Extracranial metastasis sites correlate to the incidence risk of brain metastasis in stage IV non-small cell lung cancer: a population-based study.
    J Cancer Res Clin Oncol. 2023 Feb 2. doi: 10.1007/s00432-022-04548.
    PubMed         Abstract available

    J Clin Oncol

  26. SCHULTZ KAP, Harris AK, Nelson AT, Watson D, et al
    Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry.
    J Clin Oncol. 2023;41:778-789.
    PubMed         Abstract available

  27. BENJAMIN DJ, Nagasaka M
    Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?
    J Clin Oncol. 2023;41:742-744.

  28. WIDDER J
    Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy.
    J Clin Oncol. 2023;41:938-939.

  29. GONZALEZ SERRANO A, Laurent M, Barnay T, Martinez-Tapia C, et al
    A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
    J Clin Oncol. 2023;41:826-834.
    PubMed         Abstract available

  30. CULAKOVA E, Mohile SG, Peppone L, Ramsdale E, et al
    Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.
    J Clin Oncol. 2023;41:835-846.
    PubMed         Abstract available

  31. HERBST RS, Wu YL, John T, Grohe C, et al
    Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    J Clin Oncol. 2023 Jan 31:JCO2202186. doi: 10.1200/JCO.22.02186.
    PubMed         Abstract available

  32. NOVELLO S, Kowalski DM, Luft A, Gumus M, et al
    Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
    J Clin Oncol. 2023 Feb 3:JCO2201990. doi: 10.1200/JCO.22.01990.
    PubMed         Abstract available

    The Intersection of Lung Cancer Screening, Radiomics, and Artificial Intelligence: Can One Scan Really Predict the Future Development of Lung Cancer?
    J Clin Oncol. 2023 Feb 3:JCO2202885. doi: 10.1200/JCO.22.02885.

    J Surg Oncol

  34. KARAM E, Tabutin M, Dupre A
    Neither surveillance nor treatment showed significant survival benefit for lung metastases from colorectal cancer, imaging guided thermal ablation is a safe and efficient alternative to surgery.
    J Surg Oncol. 2022 Nov 17. doi: 10.1002/jso.27148.

  35. TREASURE T, Macbeth F
    Finding that outcomes after imaging-guided thermal ablation and surgery for colorectal lung metastases are similar does not prove a survival benefit from either.
    J Surg Oncol. 2023;127:510-512.

  36. HONG JH, Swami N, Dee EC, Gomez SL, et al
    Non-small cell lung cancer disparities in stage at presentation and treatment for Asian American, Native Hawaiian, and Pacific Islander women.
    J Surg Oncol. 2023 Jan 31. doi: 10.1002/jso.27204.
    PubMed         Abstract available

    J Thorac Oncol

  37. KILLINGBERG KT, Gronberg BH, Slaaen M, Kirkevold O, et al
    Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer.
    J Thorac Oncol. 2023 Jan 27:S1556-0864(23)00016.
    PubMed         Abstract available

    JAMA Oncol

  38. ASLAN V, Yazici O, Ozdemir N
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7586.

  39. RICCIUTI B, Wang X, Awad MM
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7589.

  40. ZHANG X, Zhang L
    Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade.
    JAMA Oncol. 2023 Feb 2. doi: 10.1001/jamaoncol.2022.7583.

    Lancet Oncol

  41. DONG YM, Sun SZ, Ding SS, Chen HM, et al
    Pseudoprogression of a cutaneous lung cancer metastasis.
    Lancet Oncol. 2023;24:e102.

    Mol Cancer Ther

  42. LI X, Zhou S, Abrahams CL, Krimm S, et al
    Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
    Mol Cancer Ther. 2023;22:155-167.
    PubMed         Abstract available

    PLoS One

  43. ZHENG Z, Hu Y, Ren Y, Mo G, et al
    Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study.
    PLoS One. 2023;18:e0267809.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  44. LI H, Liu Y, Xiao Y, Wilson CN, et al
    CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors.
    Proc Natl Acad Sci U S A. 2023;120:e2212072120.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.